New Releases from NCBI BookshelfVanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].Vanzacaftor-Tezacaftor-Deutivacaftor (Alyftrek): Indication: For the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Alyftrek be reimbursed by public drug plans for the treatment of cystic fibrosis (CF) […]
